2024
52284 Influence of Biological Sex on Clinical Manifestation in Moderate-to-Severe Atopic Dermatitis and on Dupilumab Treatment Effectiveness
Zink A, Beck L, Lebwohl M, Gooderham M, Strober B, Maul J, Pinter A, Johansson E, Chen Z, Hagen S, Bastian M. 52284 Influence of Biological Sex on Clinical Manifestation in Moderate-to-Severe Atopic Dermatitis and on Dupilumab Treatment Effectiveness. Journal Of The American Academy Of Dermatology 2024, 91: ab240. DOI: 10.1016/j.jaad.2024.07.952.Peer-Reviewed Original ResearchP101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study
Wang Z, Yang M, Chao J, Martins B, Chuang C, Shumel B, Sierka D, Carboni M, Strober B. P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study. British Journal Of Dermatology 2024, 191: i63-i64. DOI: 10.1093/bjd/ljae090.128.Peer-Reviewed Original ResearchAtopic dermatitisEpisodes of itchingTreatment satisfactionMonth 1Disease controlClinical practiceProportion of patientsPatient survey studyPercentage of patientsSustained improvementFollow-up resultsPrescribed dupilumabGeneralized estimating equationsQuality of lifePatient support programmeSingle-armDupilumabSkin symptomsBaseline surveyPatientsSupport programmesPatient satisfactionPractice guidelinesStatistical significanceMonthsCharacterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry
Silverberg J, Cronin A, Jones E, Dave S, McLean R, Greenberg J, Strober B, Bieber T, Gooderham M, Paller A, Simpson E. Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry. JAAD International 2024, 15: 127-130. PMID: 38545488, PMCID: PMC10966280, DOI: 10.1016/j.jdin.2023.11.015.Peer-Reviewed Original Research503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
Wang Z, Martins B, Ardeleanu M, Yang M, Bégo-Le-Bagousse G, Sierka D, Strober B. 503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice. British Journal Of Dermatology 2024, 190: ii9-ii9. DOI: 10.1093/bjd/ljad498.011.Peer-Reviewed Original ResearchHealth statusIndividual patient levelTreatment satisfactionAtopic Dermatitis Control ToolPatient levelQuality of life of childrenObservational study of adultsAtopic dermatitisLongitudinal cohort studyPatient-reported outcomesPatient support programStudy of adultsQuality of lifeDupilumab treatmentMonth 1Lives of childrenBaseline surveyChronic inflammatory skin diseasePatients maintained responseSupport programsModerate-to-severe ADCohort studyLong-term treatmentInflammatory skin diseaseOutcome trajectories
2023
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
Silverberg J, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson E, Li P, Longphre M, Song J, Guo J, Yun J, Williams B, Pan W, Ho S, Collazo R, Wei Z. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001). Journal Of Allergy And Clinical Immunology 2023, 153: 1040-1049.e12. PMID: 38157942, DOI: 10.1016/j.jaci.2023.11.924.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsEczema Area Severity IndexSevere atopic dermatitisSecondary endpointsAtopic dermatitisWeek 16Serious treatment-emergent adverse eventsNext-generation monoclonal antibodiesPhase 2 trialInjection site reactionsSignificant percent reductionQ4w dosingPrimary endpointTreatment discontinuationAdverse eventsCurrent therapiesLower incidenceQ2WIL-4RαUnspecified causesPandemic-related restrictionsQ4WTrial conductPlaceboMonoclonal antibodiesLong-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
Kimball A, Delevry D, Yang M, Chuang C, Wang Z, Bégo-Le-Bagousse G, Martins B, Wu E, Shumel B, Wang J, Sierka D, Chao J, Strober B. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study. Dermatology And Therapy 2023, 13: 2107-2120. PMID: 37552431, PMCID: PMC10442302, DOI: 10.1007/s13555-023-00965-5.Peer-Reviewed Original ResearchPatient-reported outcomesAtopic Dermatitis Control ToolAD therapyDermatology Life Quality IndexActivity Impairment QuestionnaireLong-term therapyLife Quality IndexLong-term treatmentPatient-reported benefitsPatient support programClinical practice settingReal-world studyAdequate disease controlLong-term effectivenessDupilumab useImpairment QuestionnaireSevere ADAD medicationsAtopic dermatitisTherapy useSkin symptomsCurrent therapiesSleep problemsDupilumabPractice settingsAbrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, Beck L, de Bruin‐Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura M, Chan G, Farooqui S, Kerkmann U, Clibborn C. Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 2047-2055. PMID: 37319109, DOI: 10.1111/jdv.19254.Peer-Reviewed Original ResearchConceptsSevere atopic dermatitisPatient-reported outcomesAbrocitinib 200Phase 3 studyAtopic dermatitisWeek 48POEM scoresDermatology Life Quality Index scoresLong-term extension studyLife Quality Index scoresEczema Measure scoreManageable safety profilePatient-reported endpointsMean DLQI scorePatient-reported symptomsProportion of patientsPatient-reported responsesFull treatment periodPhase 3Quality Index scoresDLQI 0/1DLQI scoreWeek 12AD trialsSafety profileAbrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, Beck L, de Bruin‐Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura M, Chan G, Johnson S, Farooqui S, Kerkmann U, Clibborn C. Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 2056-2066. PMID: 37335885, DOI: 10.1111/jdv.19280.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsSevere atopic dermatitisSerious treatment-emergent adverse eventsPhase 3 studyAtopic dermatitisSafety profileAbrocitinib 200Frequent treatment-emergent adverse eventsLong-term extension studyUpper respiratory tract infectionLong-term safety profileChronic atopic dermatitisManageable safety profileProportion of patientsRespiratory tract infectionsFull treatment periodLong-term efficacyLong-term safetyPruritus improvementSkin clearanceEfficacy endpointSafety endpointAdverse eventsTract infectionsAD trialsJAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
Shahriari N, Strober B, Shahriari M. JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients. JAAD Case Reports 2023, 33: 81-83. PMID: 36873051, PMCID: PMC9982443, DOI: 10.1016/j.jdcr.2023.01.020.Peer-Reviewed Original Research
2022
33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
Strober B, Chao J, Chuang C, Yang M, Shumel B, Wang J, Bego-Le-Bagousse G, Sierka D, Wang Z, Delevry D. 33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study. Journal Of The American Academy Of Dermatology 2022, 87: ab159. DOI: 10.1016/j.jaad.2022.06.669.Peer-Reviewed Original Research33325 Long-term dupilumab effectiveness on health-related quality of life (HRQoL) and work productivity in atopic dermatitis (AD): Results from RELIEVE-AD
Delevry D, Chao J, Chuang C, Yang M, Shumel B, Martins B, Bego-Le-Bagousse G, Sierka D, Wang Z, Strober B. 33325 Long-term dupilumab effectiveness on health-related quality of life (HRQoL) and work productivity in atopic dermatitis (AD): Results from RELIEVE-AD. Journal Of The American Academy Of Dermatology 2022, 87: ab179. DOI: 10.1016/j.jaad.2022.06.749.Peer-Reviewed Original Research310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis
Gooderham M, Strober B, Ardern-Jones M, Guttman-Yassky E, Levenberg M, Chan G, Biswas P, Watkins M. 310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis. Journal Of Investigative Dermatology 2022, 142: s53. DOI: 10.1016/j.jid.2022.05.318.Peer-Reviewed Original ResearchTreatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis
Strober B, Mallya U, Yang M, Ganguli S, Gadkari A, Wang J, Sierka D, Delevry D, Kimball A. Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis. JAMA Dermatology 2022, 158: 142-150. PMID: 34910086, DOI: 10.1001/jamadermatol.2021.4778.Peer-Reviewed Original ResearchConceptsAtopic Dermatitis Control ToolHealth-related qualityPatient-reported outcomesAtopic dermatitisMonth 12Disease controlCohort studySkin symptomsMonths 1AD therapyDermatology Life Quality IndexStand-alone questionsActivity Impairment QuestionnaireSevere atopic dermatitisClinical trial populationsNumerical rating scaleLife Quality IndexPatient support programQuality of lifeAdequate disease controlDupilumab useSystemic corticosteroidsImpairment QuestionnaireMost patientsTreatment satisfaction
2021
Getting personal about skin: Realizing precision medicine in dermatology
Brownstone N, Wu J, Strober B, Dickerson T. Getting personal about skin: Realizing precision medicine in dermatology. Dermatological Reviews 2021, 2: 289-295. DOI: 10.1002/der2.99.Peer-Reviewed Original ResearchDisease statesImproved clinical outcomesPersonalized medicinePrecision medicine toolsEfficient patient careAtopic dermatitisClinical outcomesTreatment paradigmIndividual patientsField of dermatologyPatient carePatientsMedicine toolsTreatment of diseasesMedicine testsHealthcare expendituresClinical dermatologyDermatologyHealthcare systemPrecision medicineTreatmentDiagnosisPersonalized medicine testsBiomarkersMedicine25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5
Kwatra S, Forman S, Cruz A, Ball S, DeLozier A, Pierce E, Buchanan A, Sun L, Ding Y, Strober B. 25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5. Journal Of The American Academy Of Dermatology 2021, 85: ab59. DOI: 10.1016/j.jaad.2021.06.260.Peer-Reviewed Original Research
2017
Janus Kinase Inhibitors
Kim A, Strober B. Janus Kinase Inhibitors. 2017, 187-198. DOI: 10.1007/978-3-319-66884-0_19.Peer-Reviewed Original ResearchAutoinflammatory disordersJanus kinase inhibitorNovel drug classJanus kinaseMedication classesAtopic dermatitisRheumatoid arthritisAlopecia areataHematologic disordersClinical dataDrug classesPolycythemia veraTherapeutic benefitJAK inhibitorsNew agentsJAK-STAT pathwayClinical useJakinibsKinase inhibitorsActivator of transcriptionDisordersPreliminary findingsSignal transducerInhibitorsHuman use
2013
Treatment of atopic dermatitis in pregnancy
Babalola O, Strober B. Treatment of atopic dermatitis in pregnancy. Dermatologic Therapy 2013, 26: 293-301. PMID: 23914886, DOI: 10.1111/dth.12074.Peer-Reviewed Original Research
2010
Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial
Bangert C, Strober B, Cork M, Ortonne J, Luger T, Bieber T, Ferguson A, Ecker R, Kopp T, Weise-Riccardi S, Guettner A, Stingl G. Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. Dermatology 2010, 222: 36-48. PMID: 21150167, DOI: 10.1159/000321711.Peer-Reviewed Original ResearchConceptsPimecrolimus cream 1End of studyCream 1Vehicle creamTopical pimecrolimusAD lesionsAtopic dermatitisDouble-blind treatmentDermal dendritic cellsProportion of patientsAtopic dermatitis lesionsNumber of leukocytesAD remissionEczema AreaPlacebo creamSubclinical inflammationTopical corticosteroidsControlled TrialsDendritic cellsInflammatory infiltrateLangerhans cellsNonsignificant reductionSkin biopsiesT cellsOutcome measures